Get updates on drug lawsuits, settlements and PAL news

Are You Fed Up with High Drug Prices? Get Involved. Tell Us Your Story.

Testimony & Comments

PAL and our coalition members often submit testimony and comments to federal agencies on a variety of issues related to the pricing and marketing of prescription drugs. Below are copies of some of the recent comments we have submitted.

Comments of PAL and Community Catalyst concerning a proposed FDA study on the effect of drug coupons in direct to consumer advertising upon consumer perceptions of drug risks and benefits. (Nov. 22, 2010)

Comments of PAL and 22 other groups concerning FDA notice on Direct–to-Consumer Prescription Drug Advertisements (June 24, 2010)

Comments of PAL, The Prescription Project, National Physicians Alliance and US PIRG on FDA's Draft Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices (April 21, 2008)
Comments of PAL & 26 other organizations to FDA on proposed study of drug advertisements (October, 2007)
Comments to Federal Trade Commission on AUthorized Generics Study (June, 2006)
Comments of PAL & 23 other orgnaizations to FDA on proposed study of prescription drug coupons, calling for ban on such coupons (April 2006)
Testimony of PAL at FDA hearing on Direct-to-Consumer Advertising of Prescription Drugs (November 2005)

Testimony & Comments

A Community Catalyst Initiative

Your Interest Area: